RESUMO
Quality standards (QS) are measurable constructs designed to quantify gaps in care and subsequently to improve quality of care. The Assessment of SpondyloArthritis International Society (ASAS) recently generated and published international QS for the management of patients with axial spondyloarthritis (axSpA) for the first time. The German Society of Rheumatology (DGRh) then decided to translate, review and possibly adopt these standards by a group of experts from different care settings. Against this background, national QS for the management of patients with axSpA for Germany were developed for the first time. The main focus was on feasibility and practical relevance. Ultimately, nine QS were defined with which the quality of care in Germany can and should be measured and improved.
Assuntos
Espondiloartrite Axial , Reumatologia , Espondilartrite , Espondilite Anquilosante , Humanos , Espondilartrite/diagnóstico , Espondilartrite/terapia , AlemanhaAssuntos
Anticorpos Monoclonais Humanizados/economia , Anticorpos Monoclonais Humanizados/uso terapêutico , Antirreumáticos/economia , Antirreumáticos/uso terapêutico , Cobertura do Seguro/economia , Cobertura do Seguro/legislação & jurisprudência , Isoxazóis/economia , Isoxazóis/uso terapêutico , Programas Nacionais de Saúde/economia , Programas Nacionais de Saúde/legislação & jurisprudência , Uso Off-Label/economia , Uso Off-Label/legislação & jurisprudência , Inibidores do Fator de Necrose Tumoral , Adalimumab , Idoso , Progressão da Doença , Custos de Medicamentos/legislação & jurisprudência , Quimioterapia Combinada , Medicina Baseada em Evidências/legislação & jurisprudência , Prova Pericial/legislação & jurisprudência , Feminino , Humanos , Seguro de Serviços Farmacêuticos/economia , Seguro de Serviços Farmacêuticos/legislação & jurisprudência , Isoxazóis/efeitos adversos , Leflunomida , Metotrexato/efeitos adversos , Metotrexato/uso terapêutico , Prednisolona/economia , Prednisolona/uso terapêuticoRESUMO
At the Spondyloarthropathy (SpA) Congress 2010 new results were presented on the pathophysiology, imaging and therapy of this disease. With a better understanding in particular of the bone biology, the causes of the disease-specific alterations in bone could be explained in the future so that new therapy options can be developed. Magnetic resonance imaging is a milestone for a better understanding of the pathophysiology of SpA. Against the background of the pressure of increasing costs in the healthcare system and cost-intensive biologics it was discussed how well the therapeutic response to TNFα antagonists can be predicted. In connection with this it was critically commented that in the clinical routine time limited attempts at therapy in order to decide how the therapy should be continued depending on the response would be more useful than to make a strict selection of patients based on predictors.
